AUS
NZ
UK
CA
USA
IND
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is exceeding expectations in FY 2024, as evidenced by its robust performance on the ASX 200. The company's share price surged by 7.66% to AU$24.17 on 22 March 2022, signaling a strong finish to the week.
Investor enthusiasm surged following the release of an update on the company's guidance for FY 2024. Previously, Fisher & Paykel Healthcare had projected operating revenue of approximately NZ$1.7 billion and a net profit after tax ranging from NZ$250 million to NZ$260 million, based on a NZ:US exchange rate of 58 cents.
However, with the assumption of a NZ:US exchange rate of approximately 61 cents for the remainder of the financial year, the company anticipates full-year operating revenue of around NZ$1.73 billion. Additionally, it expects underlying profit after tax, excluding any fair value changes, to fall within the range of approximately NZ$260 million to NZ$265 million.
What is driving this remarkable performance? According to Lewis Gradon, Fisher & Paykel Healthcare's managing director and CEO, strong demand in the Hospital products segment has persisted throughout the second half of the year. Gradon highlighted the solid demand for hospital consumables across the product portfolio, surpassing expectations set in November.
Furthermore, demand for the company's Evora Full obstructive sleep apnoea (OSA) mask has been notable. Gradon expressed optimism about the positive reception of the F&P Solo mask, introduced in early markets, and anticipates its rollout in more countries in the coming months.
Despite these positive developments, news of an expected revaluation of some properties could not dampen investor enthusiasm. Fisher & Paykel Healthcare anticipates a potential reduction in the valuation of properties in Auckland and Mexico due to higher interest rates and zoning status. However, the extent of the impact remains uncertain, and any reduction in property value will be recognized as a non-cash accounting adjustment in the income statement, affecting reported net profit after tax for the year.
Despite these considerations, Fisher & Paykel Healthcare's shares have gained an impressive 19% over the last six months, reflecting investor confidence in the company's performance and growth prospects.
